[8-K] iBio, Inc. Reports Material Event

Rhea-AI Filing Summary

On June 24, 2025, iBio, Inc. (Nasdaq: IBIO) filed a Form 8-K to inform the market that it has released an updated corporate presentation, dated June 2025. The slide deck, furnished as Exhibit 99.1, will be used in discussions with investors, analysts and other stakeholders. The filing is made under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). iBio states that the presentation includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995 and that the company assumes no obligation to update the material. No financial results, strategic transactions or other material developments are disclosed in this report.

Insights

Financial Analyst

TL;DR: Routine 8-K; only announces new investor deck, no financial impact.

This filing merely furnishes an updated corporate presentation without providing revenue figures, guidance changes or operational milestones. Such disclosures are standard IR housekeeping and typically do not influence valuation or near-term trading. The lack of new data or transactional details makes the event neutral from a financial perspective.

Corporate Governance Expert

TL;DR: Standard Regulation FD communication, maintains disclosure compliance.

By filing the presentation under Items 7.01 and 8.01, iBio satisfies Regulation FD, ensuring equal information access. Inclusion of safe-harbor language follows best practice. There are no governance concerns or obligations triggered, and the company expressly limits any duty to update, keeping legal exposure minimal.

0001420720false00014207202025-06-242025-06-24

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 24, 2025

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

​	​
001-35023	26-2797813
(Commission File Number)	(IRS Employer Identification No.)

​

11750 Sorrento Valley Road, Suite 200

San Diego, California 92121

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​	​	​
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

​

​

​

​

Item 7.01. Regulation FD Disclosure.

​

iBio, Inc. (the “Company”) has updated its corporate presentation. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.

​

The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

​

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

​

Item 8.01. Other Events.

​

The Company has updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

​

Item 9.01.     Financial Statements and Exhibits.

​

(d) Exhibits

​

Exhibit No.		Description
​	​	​
99.1	​	Corporate Presentation of iBio, Inc., dated June 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

Date: June 24, 2025	IBIO, INC.
	By:	/s/ Marc A. Banjak
		Name: Marc A. Banjak
		Title: Chief Legal Officer

​

​

FAQ

Why did iBio (IBIO) file a Form 8-K on June 24, 2025?

To furnish an updated corporate presentation for investors, analysts and other stakeholders.

What is contained in Exhibit 99.1 of iBio's June 2025 Form 8-K?

Exhibit 99.1 is the company’s new corporate presentation dated June 2025.

Does the 8-K disclose any financial results or guidance changes for IBIO?

No. The filing does not include earnings data, revenue figures or updated guidance.

Are there any major transactions announced in this IBIO filing?

No. The report mentions no acquisitions, financings or other material transactions.

How can investors access iBio’s updated investor deck?

It is available as Exhibit 99.1 within the SEC’s EDGAR system alongside the Form 8-K.